BioCentury | Nov 17, 2018
Product Development

MyoKardia’s myosin mechanism deconvolution

With preclinical proof of concept that its lead candidate mavacamten acts via two distinct mechanisms to treat cardiomyopathy, MyoKardia Inc. is ready to accelerate a pipeline of preclinical programs that exploit the mechanisms separately for...
BioCentury | Jul 4, 2011

2Q Stock Wrap-Up: Stand and deliver

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals. The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the...
BC Week In Review | May 23, 2011
Clinical News

Calsed amrubicin: Phase III data

The open-label, international Phase III ACT-1 trial in 637 patients showed that IV amrubicin as second-line therapy missed the primary endpoint of significantly improving OS vs. topotecan (7.5 vs. 7.8 months, p=0.17). Amrubicin also missed...
BioCentury | May 23, 2011

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.67 (14%) to $30.38 on Friday, while partner Biogen Idec Inc. (NASDAQ:BIIB) was up $0.39 to $97.11, after EMA's CHMP reversed a prior decision and recommended conditional approval...
BC Extra | May 20, 2011
Clinical News

Amrubicin misses in lung cancer

Second-line treatment with amrubicin from Celgene Corp. (NASDAQ:CELG) missed the primary endpoint of significantly improving overall survival vs. topotecan in the Phase III ACT-1 trial to treat small cell lung cancer (SCLC), according to an...
BC Extra | Oct 12, 2004
Clinical News

COM completes enrollment in fibrillation Phase III

Cardiome (TSE:COM; CRME) completed enrollment of 420 patients with atrial fibrillation in the Phase III ACT-1 trial of its RSD1235 antiarrhythmic. The primary endpoint is acute conversion to normal heart rhythm in recent-onset patients. The...
Items per page:
1 - 6 of 6